Jazz Pharmaceuticals PLC
JAZZ Healthcare Biotechnology
Jazz Pharmaceuticals PLC’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, up 4.88% from fiscal 2024. In the quarter to June 2026, revenue grew 15.6%, EPS grew 126.0%, free cash flow grew 141.0% and total debt fell 18.9%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.
Follow JAZZ
Jazz Pharmaceuticals PLC (JAZZ) P/E ratio
As of 16 October 2026, Jazz Pharmaceuticals PLC (JAZZ) trades at a P/E ratio of 13.8×. Over the past ten years it has ranged from 0.0× (March 2026) to 522× (June 2026); the current reading is higher than 29% of that period. That is above the Biotechnology industry median of 8.5× and below the Healthcare sector median of 23.0×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 13.5× | (30.24%) |
| FY2023 | 19.4× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 38.3× | 136.52% |
| FY2019 | 16.2× | (2.56%) |
| FY2018 | 16.6× | (1.68%) |
| FY2017 | 16.9× | (2.35%) |
| FY2016 | 17.3× | (33.75%) |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 15.8× | (96.16%) |
| Mar 2026 | 411× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 42 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| SMMT Summit Therapeutics PLC compare | n/m |
| BBIO BridgeBio Pharma, Inc. compare | n/m |
| JAZZ Jazz Pharmaceuticals PLC | 13.8× |
| ASND Ascendis Pharma A/S compare | 16.3× |
| EXEL Exelixis, Inc. compare | 18.8× |
| HALO Halozyme Therapeutics, Inc. compare | 34.6× |
| TECH Bio-Techne Corp compare | 62.0× |
| BMRN BioMarin Pharmaceutical Inc. compare | 144× |
| CORT Corcept Therapeutics Incorporated compare | 212× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)